SR-46349B
SR-46349B
SR-46349B is a chemical compound that acts as a selective antagonist of the 5-HT2B receptor, a subtype of the serotonin receptor. It has been extensively studied for its potential therapeutic applications and its role in understanding the pharmacology of serotonin receptors.
Chemical Structure and Properties[edit | edit source]
SR-46349B is a synthetic compound with the chemical formula C19H21FN2O2. It is characterized by its selective binding affinity to the 5-HT2B receptor, which distinguishes it from other serotonin receptor antagonists that may have broader activity across multiple receptor subtypes.
Pharmacology[edit | edit source]
SR-46349B functions primarily as a 5-HT2B receptor antagonist. The 5-HT2B receptor is one of the several subtypes of serotonin receptors, which are G protein-coupled receptors involved in various physiological processes, including mood regulation, cardiovascular function, and gastrointestinal motility.
Mechanism of Action[edit | edit source]
By blocking the 5-HT2B receptor, SR-46349B inhibits the action of serotonin (5-HT) at this receptor site. This blockade can modulate various biological responses, making SR-46349B a valuable tool in research to delineate the specific roles of 5-HT2B receptors in health and disease.
Therapeutic Potential[edit | edit source]
Research into SR-46349B has suggested potential applications in treating conditions where 5-HT2B receptor activity is implicated. These include certain cardiovascular diseases, fibrotic disorders, and possibly some psychiatric conditions. However, its use in clinical settings is primarily investigational.
Research and Development[edit | edit source]
SR-46349B has been used extensively in preclinical studies to explore the role of 5-HT2B receptors. These studies have provided insights into the receptor's involvement in cardiac valvulopathy, pulmonary hypertension, and other pathophysiological conditions.
Safety and Toxicology[edit | edit source]
As with many receptor antagonists, the safety profile of SR-46349B is an important consideration. While it has shown promise in research settings, its safety and efficacy in humans require further investigation through clinical trials.
Also see[edit | edit source]
Template:Receptor pharmacology
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
